@entity900 and @entity136 in @entity1 with XXXX ( @entity1125 ) and persistent jaundice despite optimal stenting: Effective intervention in @entity1 with luminal disease.

@entity1 @entity137 @entity648 @entity900 @entity3 @entity253 @entity136 @entity1125 @entity1349
INTRODUCTION: The @entity1125 ( @entity1125 )-02 study established @entity900 and @entity136 (CisGem) as a reference 1(st)-line regimen for @entity1 with advanced/metastatic @entity1125 ; @entity1 with @entity648    1.5  * upper limit of normal (ULN) were excluded and there are few extant data for systemic treatment in the context of elevated @entity648 . METHODS: @entity1 with @entity1125 , receiving CisGem with a baseline @entity648 of    1.5*ULN were eligible for this retrospective analysis; response, @entity137 and survival data were collected. RESULTS: Thirty-three @entity1 of 545 screened; median age 59years, range 23-79; 58% male, 58% with @entity3 (79% in the liver) of performance status (PS) 0 (33%), 1 (64%) or 2 (3%) were eligible. The median baseline @entity648 was 55 mol/L (range 32-286); due to @entity253 ( @entity253 , 76%) or liver @entity3 (LM, 24%). @entity137 was comparable to the @entity1125 -02 study; @entity648 normalised in 64% during chemotherapy/follow-up. The median progression-free survival (PFS) was 6.9months (95% confidence interval (CI): 4.4-9.0) and median @entity1349 ( @entity1349 ) 9.5months (95% CI: 5.7-12.8). @entity1 with @entity253 had a longer PFS and @entity1349 than those with LM (7.0 versus 2.6months; p=0.1633 and 9.8 versus 4.4months, hazard ratio (HR) 0.74; p=0.465, respectively); not statistically significant (due to small sample size). Normalisation of @entity648 and completion of eight CisGem cycles were associated with longer @entity1349 (11.4 versus 2.9months, HR 0.49; p=0.08 and 15.2 versus 5.4months, HR 0.12 p<0.001, respectively). No difference in @entity1349 was shown between the @entity648 percentiles (for either PFS or @entity1349 ). CONCLUSION: For PS 0-1 @entity1 with @entity1125 and high @entity648 due to luminal disease despite optimal stenting CisGem can be used safely with results similar to those in @entity1 with normal @entity648 .
